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Heterologous anti-lymphocyte serum (ALS)  1 is widely used as an immunosuppres- 
sive agent, and may represent an important  intermediate  stage  in  the endeavor  to 
achieve a  narrowing of the  target,  affected  by immunosuppression.  Two questions 
arise in this context; the first concerns the specificity of immunosuppressive antibodies 
and the second concerns the mechanism by which such antibodies exert  their central 
effect on the immune system. 
ALS contains antibodies which appear to have specificity for cell populations which 
are not the primary target of immunosuppression (1, 2). Some antibodies of this type 
can be demonstrated in vitro, but seem to have little effect in vivo (3, 4); others may 
have in vivo activity, but have so far only been detected by their general toxicity in 
the host and not by a target-defined activity. Thus the development of techniques for 
the discrimination between immunosuppressive and toxic antibodies is  a  crucial re- 
quirement for the functional purification of ALS. 
ALS appears to cause inactivation of circulating lymphocytes and it is tempting to 
assume that this inactivation is due to cytotoxic antibody and thus results in immuno- 
suppression  (5,  6).  However  the immunosuppressive potency of  ALS does not cor- 
relate with its content in agglutinating and cytotoxic antibodies directed against host 
lymphocytes  (7-9).  In  fact,  ALS preparations  can  be  potent  immunosuppressive 
agents and yet be virtually devoid of lymphocytotoxic  antibodies (8).  This may be due 
to an in vivo process of destruction or inhibition which does not involve cell  lysis (3, 
10, 11). Indeed, suppression by allotype antibodies, which shows some analogies with 
ALS-mediated suppression, has been found to be independent  of late acting comple- 
ment components and hence of cell lysis (12). 
In an attempt to analyze the role of cytotoxic antibodies, we have compared 
the survival times of allografts on ALS-treated strains of C5 (MuB1)-deficient 
and C5 (MuB1)-competent mice (13-16). These survival times would be differ- 
ent were cell lysis involved in ALS action. In an initial series  of experiments, 
allograft survival times were found to be longer when the ALS-treated animals 
1  Abbreviations used in this paper: ALS, anti-lymphocyte  serum; SRBC, sheep red  blood 
ceils. 
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were C5  deficient rather  than  competent  and  this suggested  that  immunosup- 
pression by ALS did not require the C5-mediated lysis of lymphocytes by cyto- 
toxic antibody,  In subsequent  experiments,  attempts  were made  to determine 
why graft-survival  times were shorter  in  the  C5  competent  group  of  animals. 
It was found that this was because ALS, in addition to having immunosuppres- 
sive properties,  contained  graft-rejecting  activity which  acted  directly  on  the 
graft and was  enhanced when C5 was  available. 
Materials and Methods 
Animals  Used.--Inbred  mice were obtained from the Jackson Laboratory,  Bar Harbor, 
Maine. Male animals, 6-10 wk of age, of the following strains, were employed: A/J, B 10.D2- 
old Sn/J, B10.D2-new Sn/J, CBA/J, C57BL/6J, DBA/1J, DBA/2J, and RF/J. Among these 
animals, the following lack MuB1 (13, 14) which is the C5 component of complement (15, 16) : 
B10.D2-old Sn/J, A/J, RF/J, DBA/2J. 
Normal  Horse Serum.--Obtained  from  Dr.  S.  Wilson  (Fraser  Laboratory,  Connaught 
Laboratories, University of Toronto, Toronto, Canada). 
MuB1-Positive  and Negative Sera.--Anlmals were bled into tubes kept in ice water. The 
blood was kept at 2°C for 2-4 hr. Sera were separated by centrifugation at 2°C and were kept 
frozen. Such serum pools were obtained from the Jackson Laboratory, or were prepared in our 
laboratory. 
MuB1 Antisera  (13).--Antisera were obtained by immunizing female mice of strain AHe/J 
with C57L/J  Q sera incorporated in complete Freund's adjuvant. The mice were bled from 
the tails; a pool was prepared from bleedings taken over 237 days after 8-17 injections. 
Preparation of ALS.--Sera, raised  in horses (922-29, HAMTS-Tech B), were prepared  by 
Dr. G. Lamoureux (Institute of Hygiene, Laval-des-Rapides, Quebec, Canada)  and were ob- 
tained from the Medical Research Council as part of their ALS project. For preparation of 
ALS 922-29, a horse was repeatedly injected with a mixture of thymus and lymph node cells 
from C57BL/6J mice. The animal received 109 cells subcutaneously on days 0, 3, 6, and 9, and 
109 cells intravenously on days 10, 14, and 21. The horse was bled on day 29. ALS HAMTS- 
Tech B was prepared in the same way but the immunizing inoculum only contained C57BL/6J 
thymus cells and the subcutaneous injections were given in Freund's adjuvant. Another equine 
ALS, the British Research standard for anti-lymphocyte serum (in vivo use), 68/65, was ob- 
tained  from  Dr.  S.  G. Anderson  (Division of Biological Standards,  National  Institute for 
Medical Research, Mill Hill, London, England). Antisera raised in rabbits,  R30/31  and 30, 
were obtained from Dr. D. A. L. Davies (Searle Research Laboratories, High Wycombe, Bucks, 
England)  and from Dr. E. M. Lance (The Hospital for Special Surgery, New York) respec- 
tively. R30-31  and 30 were prepared  by repeatedly immunizing rabbits  with  a  membrane 
fraction of mouse thymus cells. PA was obtained by the immunization of a rabbit with polyoma 
cells. The cells were from a tumor, raised in a C57BL/6J animal and carried by serial passage; 
4 X  10  s cells  in Freund's adjuvant  were injected on day 0 into the footpad  of a rabbit. The 
same cell-number was injected on day 14 and the rabbit was bled on day 21. PA was not im- 
munosuppressive, but was cytotoxie and agglutinating for thymus  cells.  R30/31  and 68/65 
were freeze-dried; other sera were stored at -20°C. Prior to use, all sera were heated  at 56°C 
for 1 hr. In some experiments, the antisera were absorbed with an equal volume of packed 
sheep red cells, as indicated in the text. Though not strictly accurate, general usage sanctions 
• the use of the term ALS to refer to sera raised by immunization with thymus  cells alone or a 
mixture of thymus and lymph node cells. 
Single Diffusion-Ring  Test (17, 18).--MuB1 antisera (0.38 ml) and glycine buffer (1.12 ml) 
were mixed at 56°C and added to glycine agarose (1.5 ml). The carefully mixed fluid was poured CINADER, JEEJEEBHOY,  KOH, AND RABBAT  83 
into the agar diffusion  plate and allowed to set. For this purpose Immuno-Plates supplied by 
Hyland Laboratories, Los Angeles, Calif., were used. A series of 24 evenly spaced wells (diam- 
eter: 3.7 mm) were punched into the gel and were filled with antigen to the rim. To establish 
suitable conditions for the test,  various dilutions of a  standard  serum were  incubated  for 
varying periods at 20.8 ° +  0.2°C; the shortest incubation time which gave reproducible re- 
sults was finally selected. The conditions chosen for the assay were as follows: the agar diffusion 
plates were sealed, kept for 4 hr at 20.8 ° +  0.2°C  and were then photographed in the Cordis 
immunodiffusion camera (Cordis  Corp.,  Miami, rFla.). Photographs were projected and the 
ring-widths of the opaque antigen antibody precipitin zones were evaluated by comparison 
with a calibration curve in which ring-widths were plotted against the logarithm of various 
concentrations of a standard preparation. 
Cytotoxicity of ALS in the Presence of Complement.--2 ml of a  1:64 dilution of ALS pool 
922-29 was added to an equal volume of phosphate-buffered saline  (pH 7.25-7.35)  containing 
10% decomplemented C57BL/6J mouse serum and  1.5 X  107  C57BL/6J thymus cells per 
milliliter. Mter 1 hr at 37°C, 0.2 ml samples of the mixture of cells and antisera were placed 
in separate test tubes and 1.5 ml of undiluted serum or serum diluted with buffer (as indicated 
in Fig. 2) was added to each tube. The serum used was obtained from guinea pigs and from 
B 10.D2-old  Sn/J and new mice. Mter 30 rain at 37°C the mixture was gently centrifuged. The 
supernatant was discarded, 0.2 ml of buffer containing 10% decomplemented syngeneie mouse 
serum and 0.3 ml of a 1:1000 dilution of trypan blue in buffer were added  to the sediment and 
gross agglutinates were then broken up  by gentle pipetting. The percentage of cells stained 
with trypan blue was determined by counting in a hemocytometer 15 min later. At least 200 
cells were counted on each occasion. 
Skin Grafting.--The method employed and the criteria used for assessing  graft  rejection 
have been previously described (19). 
Immunization with Sheep Red Blood Cells (SRBC) and Determination of Hemagglutinin 
Titers.--SRBC from freshly bled sheep were stored in Alsever's solution at 4°C and  were al- 
ways used within a week of collection. Before use they were washed  three times in 0.9% NaC1 
and  suspended  in TC199  (Difco Laboratories,  Inc., Detroit, Mich.)  before injection. Each 
mouse received 0.1 ml of a 10% suspension  of SRBC by intravenous injection. Hemagglutinin 
titers were determined on serum obtained 7 days later using a previously described method 
(20). The titer recorded was the dilution in the last well in which the cell patterns differed from 
the buttons of cells present in the control wells. All titers have been recorded in terms of log2 
of their reciprocals. 
RESULTS 
Serum C5 Levels after ALS Treatment.--Administration of ALS is accompanied 
by small,  though  significant changes in the serum levels of C5  (Fig.  1). Thus  a 
relatively late acting complement component is affected by events which follow 
treatment with ALS, 
Effect of Cytotoxic Antibody on Lymphocytes in the Absence of C5.--Fig. 2 shows 
the uptake of trypan blue by ALS-treated thymus cells in the presence of MuB1- 
negative and MuBl-positive serum.  Cytoxicity was  observed when guinea pig 
serum or MuBl-positive mouse serum was used but not when MuBl-negative 
serum served as a source of complement. Similar results were obtained in another 
experiment  in which still larger  amounts  of serum were used  as  the  source  of 
complement, 
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by lymphoid cells coated with  cytotoxic antibody,  whereas  serum  from mice 
deficient in C5  cannot.  Hence,  there is no in vitro  "by-pass"  to  compensate 
for the absence of C5, though one cannot exclude the possibility that an in vivo 
by-pass exists. 
Survival  Times  of  Allografts  on  ALS-Treated  MuB1-Posit~ve  and  Negative 
Mice.--To  test  the  effect  of  C5  on  ALS-mediated  immunosuppression  we 
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FIG. 1. The cytotoxic effect of ALS in the presence of serum from B10.D2-old  Sn/J and 
B10.D2-new Sn/J. ALS pool 922-29 was added to thymus cells from C57BL/6J mice. Normal 
serum from C5-positive mice (B10.D2-new Sn/J), from CS-negative mice, or from guinea pigs 
served as the source of complement. After 30 min at 37°C, uptake of trypan was determined. 
The percentage of cells stained with trypan blue was plotted as a function of the quantity of 
the added normal serum. 
transplanted skin across an H-2 barrier to mice which were known to lack C5. 
Graft survival times on untreated mice were compared with those found when 
mice  received  normal  sera  or  ALS.  Graft  retention  on  untreated  coisogenic 
MuBl-positive and MuBl-negative animals was identical and was not signifi- 
cantly affected by the administration of normal horse or rabbit serum. 
Graft survival times were prolonged by ALS treatment.  They were longer 
when  ALS  was  given  to  C5-deficient  rather  than  to  C5-competent  animals 
(Table I). This was found with different ALS preparations of both horse and 
rabbit origin (Table I). The effect was observed with MuBl-positive and MuB 1- CINADER, ]EEJEEBHOY~ KOH~ AND  RABBAT  85 
negative donors of various H-2 genotypes (Table II). The magnitude of the 
effect depended on the dose schedule of ALS administration (Table III). The 
period of graft retention in C5-deficient ALS-treated animals was reduced by 
the administration of serum from CS-competent mice (Table IV). On the basis 
of these observations, it appeared reasonable to assume that ALS contained 
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two populations of  antibodies  (or  one population acting on two targets)  of 
which one had an immunosuppressive effect and did not require the complete 
complement system and the other had  a  peripheral and graft-rejecting effect 
which depended on the late acting complement components. As will be seen from 
Table III, differences between graft retention in complement competent and 
deficient animals appeared to be reduced when ALS  administration was pro- 
longed. The question therefore arose whether involvement  of the complete com- 
plement system was an absolute requirement for the graft-rejecting component 
Fro. 2.  Change in the concentration of MuB1 (C5) after the administration of ALS. Male 
mice (C57BL/6J), 9 wk old, were given daily subcutaneous injections with ALS HAMTS- 
Tech B as indicated. Injections  are indicated by syringe symbols above the horizontal ordinate. 
The mice were bled on days 0, 4, 9, 16, 23, 28, 37, and 49; MuB1 concentration was determined 
by radial diffusion (18) and related to a standard  (100%). The heavy line shows the change of 
MuB 1 concentration with time, the stippled area corresponds to 2 sD. A comparison  of the MuB 1 
content in bleedings taken between days 0 and 9 with those taken between days 16 and 28 or 
days 37 and 49 showed a significant decrease in MuB1 (P < 0.1). This change is also significant 
if the level before injections (day 0) is compared with concentrations on days 4 and 9 (P  = 
0.05), on days 16, 23, and 28 (P  <  0.01) or on days 37  and 49 (P <  0.01). An initial increase 
in MuB1 concentration is seen after the first days of ALS injection (comparing MuB1 con- 
centration on day 0 and day 4; P  =  .01). 86  IbIMUNOSUPPRESSIVE  AND  GRAFT-REJECTING  ANTIBODIES 
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of ALS to exert its action, or whether it could be effective in the absence of the 
complete complement system. To answer this question,  donors as well  as re- 
cipients were injected with ALS and graft survival was measured as a function 
of the ALS dose administered to the donor. It will be seen from Table V that, 
under these circumstances, the immunosuppressive effect of ALS could be corn- 
TABLE  II 
The  Survival  of Skin  Grafts  From  Different  Donors  on  C5-Defident  (MuB1-Negatlve)  and 
C5-Competent (MuB1-Positive)  Recipients 
Donor  Graft survival 
Treatment 
Recipient  with ALS*  Days X number  Mean 4- sn  Comparison:~  Strain  H-2  MuB1  of animals 
A/J  H-2  a 
RF/J  n-2  k 
--  B10.D2-old 
B10.D2-new 
B10.D2-old 
Bl0.D2-new 
--  B10.D2-old 
B10.D2-new 
Bl0.D2-old 
B10.D2-new 
None  9 X  i,  10 X  3,  11.4  4- 1.2~  P>0.10 
II X8,12X 2, 
13 X5 
9 X  1, 10 X  I,  11.3  4- 0.8 
11X/,12X9 
--7  to  --1  18 X  1, 16 X  1,  16.8 4-  1.1]  0.002<P<0.02 
17XS,  18X  1 
11 X  1, 12 X  2,  14.2 4- 1.7 
15 X 5, 16 X  2 
None  10 X  5, 11 X  2,  10.5  ±  0.7]  P>0.10 
12X  1 
10 X  5, 11 X  2  10.3  4- 0.4) 
-7  to  -1  12 X  2, 19 X  3,  20.3  4- 4.3]  O.OOg<P<O.02 
20X 1, 22X2, 
24X3,26X  1 
10 X  2, 11 X  2,  14.7  4- 4.5J 
12X2,13  X  1, 
14X2,18  X  1, 
20X1,23  X2 
CBA/J"  H-2  k  +  B10.D2-old  None  I0 X  4, 11 X  I,  10.7  4- 0.9~  P>0.10 
12)42 
Bl0.D2-new  I0 X  4, 11 X  2,  10.6  4- 0.7J 
12XI 
Bt0.D2-old  -7  to  -1  10 X  i, 12 X  1,  21.2  4- 6.1]  O.OO2<P<O.OZ 
19X  1,20X  1, 
21X 1,22 X  I, 
23 X  3, 26 X  1~ 
34X1 
B10.D2-new  10 X  2, 11 X  2,  14.9 :t: 3.9 
12 X2,15  X2, 
16 X  2, 18 X  I, 
19X 1, 21X 1, 
22X  1 
Recipients were male animals of strain BI0.D2-old/SnJ" (MuBl-negative, H-2  d) and Bl0.D2-new/SnJ  (MuBl- 
positive, H-2d). 
* Days at which subcutaneous  (s.c.) injections with 0.25 ml of ALS  (HAMTS-Tech B) were given, day 0 
being the day of transplantation. 
Mann-Whitney U-test. Significant differences are shown in italics. CINADER~  JEEJ'EEBHOY~  KOII~  AND  RABBAT  89 
pletely eliminated, both in  MuBl-positive and in MuBl-negative recipients. 
It follows that the graft-rejecting component of ALS can decrease graft sur- 
TABLE  IIl 
Graft Retention in  Complement-Competent (BlO.Dg-New Sn/Y)  and  Complement-Deficient 
Mice (BIO.DZ-Old  Sn/Y) as a Function of the Dose Schedule of ALS Administered 
Designation  Dose  Strain of  Graft survival 
of ALS  schedule  recipient male 
prepara-  Days of s.c.  Days X number of  Mean 4- SD 
tion  injections*  animals  animals  Comparison:~ 
922-29  --7  to  --1  B10.D2-old  15 X 2, 18 X  5, 20 X 1,  19.3  4-  3.1)  P<O.O02 
21X1,2322,24X1 
B10.D2-new  12 X  1, 13 X  4, 15 X  2,  14.4 !  1.5 
16X4 
922-29  --5 to  --1  B10.D2-old  11 X  1, 13 X  1, 14 X  1,  16.9  4-  2.5]  .P<O.O02 
16X2,17X2,18X3, 
19X2,20X2 
B10.D2-new  10 X  3, 11 X  5, 12 X  1,  12.1  4-  1.5 
13 X7, 15 X  2 
922-29  q-l,  -{-5  Bl0.D2-old  11 X  8, 12 X  5, 13 X  4,  12.1  4-  1.1]  P>0.10 
14 X3  I 
Bl0.D2-new  10 X  4, 11 X  4. 12 X  6,  11.6 =k:  1.2 
13  X 3,  14  X 1 
922-29  --7  to  --1,  B10.D2-old  10 X 2, 13 X  2 ,17  X  2,  16.8 4-  5.2]  P>0.10 
q-l,  -{-5  19 X 1, 20 X 1, 22 X I, 
27XI 
B10.D2-new  11 X  1, 13 X  1, 15 X  1,  17.0 4-  2.3J 
16X1,17  X4,19XS, 
20X1 
R30/31  q-l,  -[-5  B10.D2-old  20 X  2, 21 X  1, 24 X  2,  32.3  4- 18.4]  O.O02<P<O.OZ 
25 X  2, 27 X  2, 28 X1, 
73X2 
B10.D2-new  13 X  2, 14 X  1, 18 X  1,  19.4 4-  4.2J 
19 X  2, 20 X  1, 21 X  1, 
23 X  2, 24 X1, 26 X1 
R30/31  -{-5  B10.D2-old  11 X  1, 12 X  2, 13 X  1,  14.9 -b  2.6]  P>0.10 
14 X  2, 15 X  4, 16 X  1, 
17 X1,18X1,21X1 
B10.D2-new  11 X  2, 13 X  5, 14 X  2,  14.5  4-  6.4 
15X1,16X4,17X2, 
18X1 
Mice were given several s.c. injections of ALS before and/or after transplantation  (0.25 ml/s.c, injection) 
and were grafted with skin from A/J male mice. 
* 0 being the day of transplantation; s.c., subcutaneous. 
Mann Whitney U-test. Significant differences are shown in italics. 
vival times, though much less effectively, in the absence of the complete com- 
plement system. 
Rejection of Syngeneic Grafts from ALS-Treated Donors.--The  effect of ALS 
on syngeneic grafts was examined as the final test for the postulated presence 90  IMMUNOSUPPRESSIVE  AND  GRA]?T-RE~ECTING  ANTIBODIES 
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in ALS of graft-rejecting antibody. C5-deficient and C5-competent donors were 
treated with ALS and transplantation was carried out on untreated recipients 
of the same genotype as that of the donors. In these circumstances, a graft from 
TABLE V 
Injection  of Donor and Recipient With A LS 
Dilu-  Injec-  Recipients 
tion of  t.lon 
ALS  given  B10.D2-old  B10.D2-new 
given  to 
to  recip-  Exp.  Graft survival (days X  ExI~  Graft survival (days X  Mean -4- 
donor  ient  No.  number of animals)  Mean 4- sv  No.  number of animals 
1:1  ALS  1  11 X  6, 12 X  1, 13 X  1  11.4  4- 0.7  8  11 X  6, 12X 1, 13 X  i  11.4  4- 0.7 
I:10  ALS  2  10X2,11XI,  12X1,  14.1  ~2.4  9  10XI, llX6,12X1,  11.24-0.8 
14X  1,15Xi,17  X1,  13X1 
18X1,20X1 
1:50  ALS  3  13 X  3, 14 X  3, 16 X  i,  14.3  4-  1.4  10  11 X  1,  12 X  3, 13 X  1,  13.0  4-  1.1 
17X1  14X5 
1:I00  ALS  4  10Xl,  12Xl,  15X4,  14.04-2.0  11  10X4,11X4,14X1  10.9=t=0.7 
16X1 
1:250  ALS  5  14 X  1, 15 X  3, 16 X  2,  15.6  =t=  1.2  12  12 X  2, 13 X  3, 15 X  2,  13.6  4-  1.4 
18X]  16X1 
1:1000  ALS  6  15Xl,  16X4,19X2,  17.44-2.2  13  10M3,11Xl,  13X2,  12.04-1.9 
22X1  14Xl,  15Xl 
None  ALS  7  15 X  2,  18 X  5, 20 X  1,  19.3  -4- 3.1  14  12 X  1, 13 X  4, 15 X  2,  ]4.4  :t: 1.5 
21X 1,23  X2,24X  1  16X4 
1:1  --  11  X  10  11.0  4-  0.0  11 X  10  11.0  4- 0.0 
1:10  --  10 X  7, 12 X  2  10.4  :E 0.8  10 X  9, 11 X  1  10.1  4- 0.3 
None  --  9 X  1, 10 X  3, 11 X  8,  11.4  4-  1.2  9 X  1, 10 X  I, 11 X  7,  11.3  4-  0.8 
12X2,13X5  12X9 
Comparison  Probability~  Comparison  Probability~  Comparison  Probability~ 
between*  between*  between* 
1 and 2  P>0.10  8 and 9  P>0.10 
1 and 3  P<O.O02  8 and 10  P<O.02  1 and 8  P>0.10 
1 and 4  0.014<P<0.02  8 and 11  P>0.10  2 and 9  P>0.10 
1 and 5  .P<0.002  8 and 12  0.36>P>0.32  3  and 10  P>0.05 
1 and 6  .P<O.O02  8 and 13  P  =  0.43  4 and 11  0.002<P<0.02 
1 and 7  P<O.O02  8 and 14  P<O.O02  5 and 12  P  =  0.02 
2 and 7  P<O.02  9 and 14  P<0.002  6 and 13  P  =  0.00 
3 and 7  P<O.OO2  10 and 14  0.03<P<0.10  7 and 14  P<O.O02 
4 and 7  .P<O.OO2  11 and 14  .P<O.O02 
5 and 7  P<O.02  12 and 14  P>0.I0 
6 and 7  _P>0.10  13 and 14  F<O.05 
The recipients  (B10.D2-old/SnJ  and B10.D2-new) were subcutaneously  injected on days --7 to --1  (0 being 
the day of transplantation)  with 0.25 ml of ALS 922-29.  The donors (A/J o  z ) received injections of 0.25 ml of ALS 
922-29  on days --7  to --1. The concentration  of the ALS given to the donors was different in different groups. 
ALS was heated to 56°C for 1 hr before injection. 
* Mann Whitney U-test. 
Significant differences are shown in italics. 
a  treated  MuBl-negative  donor  to  an  untreated  syngeneic  MuBl-negative 
recipient was retained throughout the period of observation. However, a graft 
from an MuBl-positive donor to an untreated syngeneic recipient was rejected 
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We have, so far, come to the conclusion that the potency of the graft-rejecting 
component of ALS depends on the intact complement system. If the potency of 
the  ilnmunosuppressive  moiety of ALS  depends  on  the  cooperation of late 
acting complement components, it does so to a  lesser degree, and it was not 
unambiguously demonstrable in the present series of experiments. 
TABLE VI 
The Effect on Graft Survival  of ALS Administration to the Donor of a  Syngeneic  Graft 
Donor and recipient 
Strain  MuBI 
Treatment of donor*  Treatment of recipient*  Graft survival (days 
X  number of animals) 
B10.D2-old  --  none 
B10.D2-old;t  --  0.1 ml C57BL/6J  (--7  to  --1) 
B10.D2-old  --  0.25 ml HAMTS-  (-7  to  --1) 
Tech B 
B10.D2-old  --  0.25 ml HAMTS-  (-7  to  --1) 
Tech B 
B10.D2-old  --  0.25 ml HAMTS-  (--7  to  --1) 
Tech B 
B10.D2-old;  --  0.25 ml HAMTS-  (-7  to  -1) 
Tech B 
0.1 ml C57BL/6J  (-7  to  --1) 
B10.D2-oId~  --  0.15 ml C57BL/6J  (-7  to  -1) 
B10.D2-old~  --  0.25 ml HAMTS-  (--7  to  --1) 
Tech B 
0AS ml C57BL/6J  (--7  to  -1) 
0.25 ml normal horse  (--7  to  --1) 
serum 
0.15 ml C57BL/6J  (-7  to  -1) 
DBA/2J  --  0.25 ml HAMTS-  (-7  to  --1) 
Tech B 
DBA/1J  +  none 
DBA/1J  -I-  0.25 ml normal horse  (-7  to  --1) 
serum 
DBA/1J  q-  0.25 ml HAMTS-  (--7  to  --1) 
Tech B 
DBA/1J  +  0.25 ml HAMTS-  (-7  to  --1) 
Tech B 
DBA/1J  4-  0.25 ml ALS 30  (-7  to  -1) 
C57BL/6J  q-  0.25 ml HAMTS-  (-7  to  --1) 
Tech B 
C57BL/6J  +  0.25 ml PA  (--7  to  --1) 
B10.D2-old:~ 
none  >143 X  10 
0.1 ml C57BL/6J  >118 X  9 
(-7 to rejection) 
none  >215  X  9 
none  >187  X  8 
none  >150 X  7 
0.1 ml C57BL/6J  12 X  2,  >118 X  9 
(-7 to rejection) 
0.15 ml C57BL/6J  >83 X  8 
(-7 to rejection) 
0.15 ml C57BL/6J  ii X  2, 13  X  2, 
(--7  to rejection)  14 ×  1,  >83  X  7 
0.15 ml C57BL/6J  >54 X  10 
(--7 to +14 and then 
weekly) 
none  >131  X  16 
none  >110 X  14 
none  >75 X  12 
none  11  X  12, 16 X  I, 
>131  X  6 
none  11  X  4,  12 X  2, 
>110 X  8 
none  11  X  6,  >110 X  6 
none  15 X  1, 16 X  1, 
>29 X  6 
none  14 X  2,  15 X  2, 
16X 1,17  X  1, 
18 X  1,  >30X2 
Animals were male and 8 wk of age. ALS was given to the donor bdore transplantation of his skin. In com- 
plement-competent  (CS-pnsltlve or MuBl-positive) animals this led to graft rejections; this was not observed 
in complement-deficlent (C5-negative or MuBl-negatlve) animals unless they were given MuBl-positive serum. 
Rejections were not observed in control experiments in which MuB1-posltive donors and recipients were given 
normal horse serum and in which MuBl-negatlve donors and recipients were given  MuBl-positive serum. 
* Number in brackets shows day of injections, day 0 being the day of transplantation. 
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SRBC-Antibody Production by CS-Deficient  and Competnet  Mice.--The effect 
on the humoral rather than the cellular component of the immune system was 
chosen to further investigate the importance of late acting components in ALS- 
mediated immunosuppression. We utilized a system in which there was no pos- 
sibility of  ALS  affecting  the  peripheral  antigenic  stimulus:  the  response  to 
SRBC  by mice pretreated with ALS which had been  absorbed with an equal 
volume of packed SRBC before use. 
The injection of ALS, freed of SRBC  antibody, reduced the production  of 
hemagglutinating  antibody  to  the  same  extent  in  complement-deficient and 
complement-competent congenic mice (Table VII). Thus the late acting comple- 
TABLE VII 
ALS-Mediated Depression of the Response to Sheep Red Cells in Complement-Competen~ 
and Deficient Congenic Mice 
Strain of 
Mice  Serum given on days  mice injected 
received  with sheep 
erythrocytes 
Number of animals havin~ a hemagglutinin titer* 
0  2  3  4  5  6  7  8  9  >9 
--  --  B 10.D2-new  8 
--  --  B10.D2-old  8 
NHS  --4,  --3,  --2,  --1  B10.D2-new  8 
NHS  --4,  --3,  --2,  -- 1  B10.D2-old  8 
ALS  -- 1  B 10.D2-new  8 
ALS  -- 1  B 10.D2-old  8 
ALS  --2,  -- 1  B10.D2-new  1  2  3  1 
ALS  -- 2,  -- 1  B 10.D2-old  1  6  1 
ALS  --3,  --2,  --1  B10.D2-new  1  1  6 
ALS  --3,  --2,  -- 1  B10.D2-old  2  3  3 
Mice were given one to four daily subcutaneous  injections of 0.5 ml of normal horse serum 
(NHS) or equine ALS (pool 922-29)  and, 24 hr after the last injection, were injected intra- 
venously with 0.5 ml of a 2% suspension of sheep erythrocytes in 0.15 ~  NaC1. 
* Titers expressed in terms of logs of their reciprocals. 
ment components did not appear to be involved in the ALS-mediated suppres- 
sion of the immune response to SRBC. We next approached this problem in an 
experimental arrangement which allowed us to confine the ALS target to spleen 
cells (21). Previous experiments have shown that the decrease in immunological 
competence of spleen cells following in  vitro incubation with ALS is directly 
proportional to the immunosuppressive potency of the ALS used and not to its 
content of lymphocyte-agglutinating and cytotoxic antibodies (6,  19-21). 
In  Vivo Antibody Production by Spleen Cells  after  In  Vitro Incubation with 
ALS.--ALS  was  decomplernented  and  absorbed  with  an  equal  volume  of 
packed SRBC  before use. Normal spleen cells (18  X  107) from C5-competent 
and deficient mice were incubated in 1 ml of ALS922-29, undiluted or diluted 
with TC199,  as indicated in Table VIII. After 30 rain at 37°C  the mixture of 94  IMMUNOSUPPRESSIVE  AND  GRAFT-REJECTING  ANTIBODIES 
spleen cells and ALS was diluted with TC199 (7 ml) and centrifuged. The sedi- 
ment was washed once,  resuspended in a mixture of SRBC  and TC199,  and 
injected intravenously into mice given cyclophosphamide (250  mg/kg body 
weight) 7-8 hr previously. There were eight mice in each experimental group 
TABLE  VIII 
Antibody  Production  by  Spleen  Cells From  CS-Deficient and  Competent  Donors After  Their 
In Vitro Incubation  With ALS 922-29 
Exp. 
No. 
Hemagglutinin 
Spleen  cells  Recipients  titets* 7 days after 
transfer of cells 
95% con- 
Strain of  Incubated  Strain  Tieatment  Mean  fidence 
donor  in  limits of 
the means 
1  none  --  B10.D2-old  none  11.4  10.5-12,3 
none  --  B10.D2-new  none  11.2  10.0-12.4 
none  --  B10.D2-old  CY~  2.2  1.8-  2.6 
none  --  B10.D2-new  CY:[:  2.8  2.0-  3.6 
B10.D2-old  --  B10.D2-old  CY:~  10.6  10.0-11.2 
B10.D2-new  --  B10.D2-new  CY:~  10.9  10.2-11.3 
2  B10.D2-old  Medium  Bl0.D2-old  CY:~  9.8  9,0-10,6 
ALS(1:128)  CY:~  10.2  9.4-11,0 
ALS(1:32)  CY~  5.5  4,5-  6,4 
ALS(I:8)  CY~  2.0  1.8-  2.2 
ALS0:1)  CY~  1.2  0.8-  1.6 
3  B10.D2-new  Medium  B10.D2-new  CY$  11.2  9.8-12.6 
ALS(l:128)  CY~  10.4  9.2-11.6 
ALS(1:32)  CY~  6.2  5.2-  7.2 
ALS (1:8)  CY~  1.4  0.4-  2.4 
ALS(I:I)  CY~  0.2  0.0-  0.8 
4  B 10.D2-old  Medium  B 10.D2-new  CY:~  10.0  9.1-10.9 
ALS(1:32)  B 10.D2-new  CY:~  4.9  4.2-  5.6 
Medium  B10.D2-old  CY1:  9.7  9.0  10.4 
ALS(t:32)  B10.D2-old  CY~;  5.0  4.9-  5.1 
ALS(l:32)  B10.D2-old  CY,:~ Bl0.D2-new serum§  5.0  4.3  5.7 
5  B10.D2-new  Medium  B10.D2-new  C¥~:  9.4  8.5-10.3 
ALS(l:32)  B10.D2-new  C¥:~  5.8  4.3-  6.3 
Medium  B 10.D2-old  CY$  9.8  8.9-10.7 
ALS(t:32)  B10.D2-old  CY$  5.9  5.0-  6.8 
ALS(I:32)  Bl0.D2-old  CY~, B10.D2-new serum§  5.6  4.9-  6.3 
Donors  and  recipients  of  spleen  cells  were  congenic  CS-deficient  (B10.D2-old  Sn/J)  and  C5-eom- 
petent  (Bt0.n2-new  Sn/J)  8-wk old male mice. Recipients  were treated  with cyclophosphamide  (CY)  or were 
left untreated  and were given SRBC (0.1 ml of a  10% suspension)  alone or in combination with 2 X  107 spleen 
cells. The spleen cells were incubated either in ALS (922-29),  previously heated at 56°C and absorbed with SRBC, 
or they were incubated with medium TC 199. The ALS, used for incubation, was undiluted  or was diluted with 
medium TC 199.7  days after the transfer,  the animals were bled and anti-SRBC  agglutination  titers were de- 
termined. 
* Titers expressed in terms of logs of their reciprocals. 
Cyclophosphamide  (250 mg/kg body weight) was injected intraperitoneally 6-8 hr before injection of sheep 
erythrocytes and spleen cells. 
§ Fresh, C5 containing serum from Bl0.D2-new  Sn/J mice was injected intravenously immediately after the 
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and each animal received 0.5 ml of TC199 containing 2 X  107 syngeneic spleen 
cells and 0.1 ml of a  10% suspension of SRBC. Hemagglutinin titers were de- 
termined on serum obtained 7 days later. If mice were treated with cyclophos- 
phamide, their response to red cells was reduced from a hemagglutination titer 
of 11 (log2 of the reciprocal titer) to a titer of 2-3. A titer of 11 was found in the 
cyclophosphamide-treated recipients of SRBC after transfer of 2 X  107 normal 
spleen  cells from  either  C5-deficient or  C5-possessing  donors (experiment 1, 
Table VIII).  If the donor cells were incubated with undiluted ALS, or with 
ALS diluted 1:8, their restorative capacity was destroyed. If they were incu- 
bated in a 1:32 dilution of ALS, restoration was 50-60 % of that obtained with 
untreated cells.  This inhibitory effect of ALS did not depend on the comple- 
ment competence of donor or recipient (experiments 2 and 3, Table VIII) and 
was not affected by the administration of serum from MuBl-positive animals 
(experiments 4 and 5, Table VIII). It follows that immunosuppression, in this 
system, is not significantly affected by the late acting components of the com- 
plement system. 
DISCUSSION 
Our observations  are compatible  with the view that ALS  can destroy grafts 
and can suppress the immune  response and that the former effect is promoted 
by late acting complement  components  while the latter is not dependent  on 
them. Questions  which arise in this context concern the validity of the experi- 
mental  model  used, the existence of two distinct types  of activities, and  the 
identity or independence  of the molecules responsible for these two antagonistic 
activities. 
It is clear that B10.D2-old and -new mice may differ in respects other than 
those already known. Both strains originate from a  cross between C57BL/10 
and DBA/2, both have H-2  d, but only B10.D2-old is deficient in MuB1 (Hc  °, 
Herzenberg et al.,  14),  and thus has at least one, but possibly more than one 
DBA/2-chromosome fragment in addition to the one found in the B10.D2-new 
strain (22, 23). It was for this reason that we did not rely on the difference be- 
tween graft retention in the two congenic strains of ALS-treated animals, but 
verified them by the transfer of CS-containing sera to deficient mice (Tables 
IV,  VI).  This  transfer  led  to  shortened graft survival  and  thus  provided a 
crucial argument which was independent of the similarity or difference of the 
congenic strains and which led to the conclusion that complement was a factor 
in the observed differences in graft survival. However, the shorter graft-survival 
times, found when the recipients of ALS possessed C5, might have been due to 
some  unknown  complement-dependent interference with  ALS-mediated  im- 
munosuppression. The strongest argument against such a view and in favor of 
graft-rejecting factors in ALS  is  based  on  the reduced survival of allografts 
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untreated recipient of a  syngeneic graft from an ALS-treated donor. On  the 
basis of these findings, it seems quite clear that ALS contains a graft-rejecting 
substance and that it can be detected and probably assayed by the rejection of 
an ALS-treated graft transferred to an untreated syngeneic C5-competent re- 
cipient. 
Levey and Medawar (10) have shown that antisera having immunosuppres- 
sire properties can be raised by immunizing rabbits with mouse epidermal cells 
and this indicates some degree of cross-reactivity between skin and lymphocytes. 
In addition,  Cohen et al.  (24)  have shown that in vitro incubation of mouse 
skin in rabbit anti-mouse skin serum can result in rejection when the skin is 
subsequently grafted on syngeneic animals. Hence it is not surprising that ALS 
can be shown to have graft-rejecting properties. However, our findings appear 
to be at variance with those reported by Guttman et al. (25) who have concluded 
that prolongation of allograft survival by ALS is largely due to a direct action 
of ALS  on the  graft.  Their observations,  though  unconfirmed  (26),  are  not 
necessarily at variance with those described in this paper. Guttman et al.  (25) 
investigated the effect of ALS on the survival of kidney allografts in rats, and 
thus differences in the grafted tissue and in the species might explain the dif- 
ferences between their findings and ours. 
The results presented in this paper strongly suggest that immunosuppression 
by ALS is not dependent on late acting complement components. If the con- 
trary were true, it should have been possible to find longer allograft-survival 
times in ALS-treated MuBl-positive rather than negative animals. The reverse 
occurred and we therefore thought it unlikely that suppression of the cellular 
immune response by ALS could depend on the presence of late acting comple- 
ment components. However, this conclusion was far from compelling as long as 
two  opposing  ALS  effects were  in  operation:  immunosuppressive  and  graft- 
rejecting activities. 
Therefore, in the next series of experiments mice were challenged with SRBC 
after pretreatment with ALS which had been fully absorbed with SRBC prior 
to use. In such a system, any direct interaction between ALS and the antigen 
can be excluded. In agreement with Barth and Carroll (27)  it was found that 
ALS was equally efficient in suppressing the humoral antibody response to SRBC 
ill CS-deficient and competent animals. 
In  a  final series  of experiments,  spleen  cells  were incubated  in  vitro with 
different dilutions of ALS. The washed cells were mixed with SRBC and were 
injected into mice rendered immunologically anergic by treatment with cyclo- 
phosphamide. In previous experiments (21) it had been shown that incubation 
with ALS decreases the immunological capabilities of spleen ceils and that this 
decrease was  directly proportional to  the immunosuppressive potency of the 
ALS, but not to its content of lymphocyte-agglutinating and cytotoxic anti- 
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immunological competence of spleen cells does not depend on the presence of C5. 
It  is  conceivable that  ALS functions in  this  system by interfering with  the 
homing of cells and  that  it  may,  for this  reason,  appear  to be complement 
independent. These considerations led us to an experimental arrangement, in 
which only 50% of the capacity of the cell population was inhibited by ALS. 
Clearly this partial inhibition reflected concentration differences in the distribu- 
tion of ALS among cells involved in antibody formation. A proportion of these 
cells, which carried less than the suppressive dose of ALS, would be inactivated 
by complement if such inactivation were to occur. The absence of i~err~ased 
immunosuppression  in  complement-competent individuals  furnishes  another 
strong argument against the involvement of late acting complement components. 
The conclusion that ALS has a  graft-damaging  as well as an immunosup- 
pressing activity is relevant to the use of ALS in clinical transplantation.  For 
the present we have tacitly assumed that the graft-damaging and the immuno- 
suppressive antibody are not identical but this remains to be explored experi- 
mentally and is clearly crucial to any practical extension of our findings (cf. 28). 
The methods  employed in  the foregoing analysis  can provide a  tool for the 
future resolution of this problem. 
SUMMARY 
Skin  allografts  survived longer  on ALS-treated, complement-deficient (C5 
negative) recipients than on ALS-treated, complement-competent (C5 positive) 
recipients. Administration  of C5-positive serum to C5-negative,  ALS-treated 
recipients resulted in reduced graft survival. A percentage of grafts from ALS- 
treated,  C5-positive donors was  rejected when transferred to untreated  syn- 
geneic recipients; this was not observed when C5-negative, syngeneic animals 
served as ALS-treated donors and untreated recipients. It was concluded that 
ALS has graft-rejecting properties which are promoted by late acting comple- 
ment  components.  Unlike  ALS-mediated  graft  rejection,  ALS-mediated  im- 
munosuppression  appeared to be independent of the late acting  complement 
components. 
The effect of ALS on the humoral response to sheep erythrocytes was  ex- 
amined  in  complement-deficient and  complement-competent mice.  Immuno- 
suppression was  determined by ALS treatment of C5-competent and  C5-de- 
ficient  mice  and  also  by  transfer  of  in  vitro ALS-treated  spleen  cells from 
C5-negative  and  C5-positive donors  to cyclophosphamide-treated recipients. 
The ability of ALS to depress the humoral response to sheep cells and to de- 
crease immunological competence of spleen cells was the same in the presence 
as in the absence of C5. 
We wish to acknowledge the financial support of the Medical Research Council (Grants 
MT-832, MA-3390, and MT-2602), the National Cancer Institute  of Canada, the Ontario 98  IMMUNOSUPPRESSIVE AND  GRAFT-REJECTING ANTIBODIES 
Heart Foundation  (Grant  No.  1-23), the  J.  H.  Cummings Foundation,  and  the  Hartford 
Foundation Inc. 
We  are  indebted  to  Dr.  Gilles Lamoureux  (Institut de  Microbiologie et  d'Hygi~ne de 
l'Universit6 de Montreal, Laval-des-Rapides, Qu6bec, Canada), and to Dr. H. E. Taylor, the 
director of the ALS trial of the Medical Research Council (Ottawa), as well as to Dr. S. G. 
Anderson, (Director, Division of  Biological Standards,  National Institute for Medical Re- 
search) for preparations of equine ALS; to Dr. D. A. L. Davies, (Searle Research Laboratories) 
and to Dr. E. M. Lance (Hospital for Special Surgery) for rabbit ALS. We are indebted to Dr. 
S. Wilson (Connaught Laboratories) for a gift of normal horse sara. The values given in lines 
7 and 9 of Table III were obtained by an undergraduate student, Mrs. Mary Soltay. 
BIBLIOGRAPHY 
1.  Thierfelder, S., E. D.  M611er, I. Kimura, P. D6rmer, and M. Eulitz. 1968. Die 
Zellspezifitiit  heterologer,  sogenannter  antilymphocytiirer  Antiseren  vom 
Kaninchen. Z. Gesamte. Exp. Mad. 147:44. 
2.  Pichlmayr,  R.  1967. Antilymphocytenserum-heutiger Stand  der  Entwicklung. 
Schweiz. Mad.  Wochenschr. 97:1624. 
3.  Levey, R.  H.,  P.  B.  Medawar.  1966. Some experiments on the action of  anti- 
lymphoid antisera. Ann. N.  Y. Acad.  Sci. 129a:164. 
4.  Gray, J. G., A. P. Monaco, M. L. Wood, and P. S. Russell. 1966. Studies on heter- 
ologous anti-lymphocyte  serum in mice. J. Immunol. 96a:217. 
5.  Gray, J. G., A. P. Monaco, M. L. Wood, and P. Russell. 1966. Studies on heterol- 
ogous  antilymphocyte serum in mice.  II. Effect  on the  immune response.  J. 
Immunol. 96b:229. 
6.  Jooste,  S.  V.,  E.  M.  Lance, R.  H.  Levey, P.  B.  Medawar,  M.  Ruskiewicz, R. 
Sharmann, and R. N. Taub. 1968. Notes on the preparation and assay of anti- 
lymphocytic serum for use in mice. Immunology. 15:697. 
7.  Jeejeebhoy, H. F. 1967. Studies on the mode of action of heterologous antilympho- 
cyte plasma. I. A comparison of the immunosuppressive properties of dog and 
rabbit anti-rat lymphocyte plasma. Transplantation.  5:273. 
8.  Antoine, B.,  T. Neveu, J.-F. Bach,  and M.  Dardenne. 1968. Activit6 immuno- 
pr6cipitante de s6rums antilymphocytes. Corr61ations avec d'autres effects. In 
Advance in Transplantation. Munksgaard, Copenhagen, Denmark. 122. 
9.  Denman, A. M., E. J. Denman, and P. H. Embling. 1968. Changes in the lifespan 
of circulating small lymphocytes in mice after treatment with antilymphocyte 
globulin. Lancet.  1:321. 
10.  Levey, R. H., and P. B. Medawar.  1966b. Nature and mode of action of anti- 
lymphocytic antiserum. Proc. Nat. Acacl. Sci.  U.S.A. 56:1130. 
11.  Everett, N. B., M. R. Schwarz,  R. W. Tylor, and W. D. Perkins. 1970. Observa- 
tion relative to the mechanism of action of antilymphoeyte serum. Fed. Proc. 
29:212. 
12.  Cinader, B., and S. Dubiski. 1968. Suppression of murine allotypic specificities  in 
animals with a complement defect and in animals with a complete hemolytic 
complement system. J. Immunol. 101:1236. 
13.  Cinader, B., S. Dubiski and A. C. Wardlaw. 1964. Distribution, inheritance, and 
properties of an antigen, MuB1, and its relation to hemolytic complement. J. 
Exp. Med. 120:897. CINADER, JEEJEEBI=IOY, KOH, AND  RABBAT  99 
14.  Herzenberg, L. A., D. K. Tachibana, L. A. Herzenberg, and L. T. Rosenberg. 1963. 
A gene locus concerned with hemolytic complement in Mus musculus. Genetics. 
48:711. 
15.  Nilsson, U. R., and H. J. Mtiller-Eberhard. 1965. Immunologic relation between 
human/3iF-globulin and mouse MuB1  (Hc). Fed. Proc. 9.4:620. 
16.  Nilsson, U. R., and H. J. Miiller-Eberhard. 1967. Deficiency of the 5th component 
of complement in mice with an inherited complement defect. J. Exp. Med. 19.5:1. 
17.  Fahey, J.  L., and E. M.  McKelvey. 1965. Quantitative determination of serum 
immunoglobulins in antibody-agar plates. J. Immunol.  94:84. 
18.  Urbach,  G.,  and  B.  Cinader.  1966. Hormonal control of MuB1  concentration. 
Proc. Sac. Exp. Biol. Med. 122:779. 
19.  Jeejeebhoy, H. F. 1967. Allograft survival prolonged by heterologous spleen cells 
in 'Millipore' diffusion chambers. Nature (London). 158:215. 
20.  Jeejeebhoy, H. F. 1965. Immunological studies on the rat thymectomized in adult 
life. Immunology. 9:417. 
21.  Jeejeebhoy, H. F., and A. G. Rabbat. 1968. In vivo antibody production by spleen 
cells after incubation in vitro with heterologous antilymphocyte plasma. Nature 
(London). 220:1350. 
22.  Snell,  G.  D.  1958. Histocompatibility genes  of the  mouse.  II.  Production and 
analysis oi isogenic resistant lines of mice. J. Nat.  Cancer Inst.  21:843. 
23.  Caren, L. D., and L. T. Rosenberg.  1965. Complement in skin grafting in mice 
Immunology. 9:359. 
24.  Cohen, M., D. Nelken, and J. H. Boss. 1969. Effects of anti-epidermis antibodies 
on autografts in rats and rabbits. Clin. Exp. Immunol.  4:247. 
25.  Guttmann, R. D., C. B. Carpenter, R. R. Lindquist, and J. P. Merrill. 1967. An 
immunosuppressive site of action of heterologous antilymphocyte serum. Lancet. 
1:248. 
26.  Cerilli, J., C. Groth, P. Taylor, and P. Daloze. 1967. The effect of donor treatment 
with  heterologous  antilymphocyte  globulin  on  kidney  homograft  survival. 
Transplantation. 5:1334. 
27.  Barth, R. F. and G. F. Carroll. 1970. Immunosuppressive effect of antilymphocyte 
serum in complement-deficient mice: evidence that immune cytolysis is not es- 
sential for ALS activity. Y. Immunol.  104:522. 
28.  Lance, E. M., P. Ford, and M. Ruszkiewicz. 1970. Use of subcellular lymphocyte 
fractions to raise antilymphocyte serum. Fed, Proc. 9.9:106. 